The extent to which AMPK signaling can be leveraged to reprogram resident and infiltrating macrophages to improve NASH prognosis remains to be tested and may represent an additive therapeutic benefit. The gene discussed is PRKAA2; the disease is metabolic dysfunction-associated steatohepatitis.